Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AMAG AMAG Pharmaceuticals (AMAG) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About AMAG Pharmaceuticals Stock (NASDAQ:AMAG) 30 days 90 days 365 days Advanced Chart Remove Ads Get AMAG Pharmaceuticals alerts:Sign Up Key Stats Today's Range$13.75▼$13.7550-Day Range$13.69▼$13.7552-Week Range$4.41▼$13.80VolumeN/AAverage Volume950,664 shsMarket Capitalization$477.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.Read More… Remove Ads Receive AMAG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AMAG Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AMAG Stock News HeadlinesAlkeus Pharmaceuticals Appoints David Arkowitz as Chief Financial OfficerOctober 31, 2024 | markets.businessinsider.comTransoft Solutions Acquires Advanced Mobility Analytics Group (AMAG)October 15, 2024 | finance.yahoo.comCrypto Genius: 12,000% in 12 months? [Here’s how]We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.April 1, 2025 | Paradigm Press (Ad)KalVista Appoints Brian Piekos as Chief Financial OfficerSeptember 10, 2024 | finance.yahoo.comFull-Life Technologies Announces the Appointment of Edward (Ted) Myles to Its Board of DirectorsJuly 22, 2024 | msn.comGlobal Iron Drugs Strategic Business Report 2024: Market to Reach $11 Billion by 2030 with Oral Segment to Account for $6.7 BillionMay 14, 2024 | finance.yahoo.comHospital Care Collaboration and Licensing Deals, 2016-2024: Benchmark Analysis of Deals Entered Into by the World's Leading Biopharma CompaniesApril 25, 2024 | finance.yahoo.comAMAG Technology Introduces Symmetry Control RoomApril 9, 2024 | finanznachrichten.deSee More Headlines AMAG Stock Analysis - Frequently Asked Questions How were AMAG Pharmaceuticals' earnings last quarter? AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its quarterly earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.27. The specialty pharmaceutical company earned $68.66 million during the quarter, compared to the consensus estimate of $64.95 million. AMAG Pharmaceuticals had a negative trailing twelve-month return on equity of 16.92% and a negative net margin of 74.93%. Read the conference call transcript. What other stocks do shareholders of AMAG Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that AMAG Pharmaceuticals investors own include Bristol-Myers Squibb (BMY), Palatin Technologies (PTN), Gilead Sciences (GILD), Meta Platforms (META), Bausch Health Companies (BHC), Netflix (NFLX) and Tesla (TSLA). Company Calendar Last Earnings5/11/2020Today4/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:AMAG CIK792977 Webwww.amagpharma.com Phone617-498-3300FaxN/AEmployees440Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($6.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-466,460,000.00 Net Margins-74.93% Pretax MarginN/A Return on Equity-16.92% Return on Assets-5.96% Debt Debt-to-Equity Ratio1.13 Current Ratio1.75 Quick Ratio1.45 Sales & Book Value Annual Sales$327.75 million Price / Sales1.46 Cash FlowN/A Price / Cash FlowN/A Book Value$7.37 per share Price / Book1.87Miscellaneous Outstanding Shares34,725,000Free FloatN/AMarket Cap$477.47 million OptionableOptionable Beta0.89 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:AMAG) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredLive Footage From Elon Musk’s “Area 51”What’s happening inside this nondescript building in South Memphis is so incredible… That Elon’s competitor...Brownstone Research | SponsoredTermination: 18F (read immediately)Have you ever heard of the government's 18F program? It helped manage digital services across the governmen...Altimetry | Sponsored“Massive Financial Reset Is Coming”The U.S. markets will see a massive reset, beginning days from now. But the "reset" isn't what you might ex...InvestorPlace | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AMAG Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AMAG Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.